• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Assessing health status after discharge for decompensated heart failure: a patient-centred priority.评估失代偿性心力衰竭出院后的健康状况：以患者为中心的重点。
Eur J Heart Fail. 2022 Jun;24(6):1030-1032. doi: 10.1002/ejhf.2521. Epub 2022 May 13.
2
A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.纳入 N 末端脑利钠肽前体水平的急性失代偿性心力衰竭患者新型出院风险模型：急性失代偿性心力衰竭的欧洲合作：ELAN-HF 评分。
Heart. 2014 Jan;100(2):115-25. doi: 10.1136/heartjnl-2013-303632. Epub 2013 Oct 31.
3
Brain-Type Natriuretic Peptide and Amino-Terminal Pro-Brain-Type Natriuretic Peptide Discharge Thresholds for Acute Decompensated Heart Failure: A Systematic Review.脑利钠肽和氨基末端脑利钠肽原在急性失代偿性心力衰竭中的释放阈值：系统评价。
Ann Intern Med. 2017 Feb 7;166(3):180-190. doi: 10.7326/M16-1468. Epub 2016 Nov 29.
4
Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure.出院前B型利钠肽检测用于识别失代偿性心力衰竭后再入院高风险患者。
J Am Coll Cardiol. 2004 Feb 18;43(4):635-41. doi: 10.1016/j.jacc.2003.09.044.
5
NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).NT-proBNP（氨基末端脑利钠肽前体）指导急性失代偿性心力衰竭治疗的研究：PRIMA II 随机对照试验（急性失代偿性心力衰竭住院期间 NT-proBNP 指导治疗能否降低死亡率和再入院率？）
Circulation. 2018 Apr 17;137(16):1671-1683. doi: 10.1161/CIRCULATIONAHA.117.029882. Epub 2017 Dec 14.
6
Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure.手持超声评估下腔静脉与N末端脑钠肽前体对急性失代偿性心力衰竭住院后再入院预测的比较
JACC Cardiovasc Imaging. 2008 Sep;1(5):595-601. doi: 10.1016/j.jcmg.2008.06.005.
7
Risk prediction for 30-day heart failure-specific readmission or death after discharge: Data from the Korean Acute Heart Failure (KorAHF) registry.出院后 30 天内心力衰竭特定再入院或死亡的风险预测：来自韩国急性心力衰竭（KorAHF）注册研究的数据。
J Cardiol. 2019 Feb;73(2):108-113. doi: 10.1016/j.jjcc.2018.07.009. Epub 2018 Oct 22.
8
Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study.实施B型利钠肽检测以决定出院后心力衰竭再入院率的下降：一项回顾性研究。
Int J Cardiol. 2008 Jun 6;126(3):400-6. doi: 10.1016/j.ijcard.2006.03.097. Epub 2007 Sep 4.
9
B-type natriuretic peptide predicts 30-day readmission for heart failure but not readmission for other causes.B型利钠肽可预测心力衰竭患者30天内再入院情况，但无法预测因其他原因导致的再入院情况。
J Am Heart Assoc. 2014 Jun 10;3(3):e000806. doi: 10.1161/JAHA.114.000806.
10
Challenging the two concepts in determining the appropriate pre-discharge N-terminal pro-brain natriuretic peptide treatment target in acute decompensated heart failure patients: absolute or relative discharge levels?在急性失代偿性心力衰竭患者中确定适当的出院前 N 末端脑利钠肽前体治疗目标时挑战两个概念：绝对或相对出院水平？
Eur J Heart Fail. 2015 Sep;17(9):936-44. doi: 10.1002/ejhf.320. Epub 2015 Jul 29.

引用本文的文献

1
Patient-reported outcomes in clinical studies of patients with hypertrophic cardiomyopathy.肥厚型心肌病患者临床研究中的患者报告结局。
Prog Cardiovasc Dis. 2023 Sep-Oct;80:60-65. doi: 10.1016/j.pcad.2023.08.007. Epub 2023 Aug 23.

本文引用的文献

1
Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure).急性心力衰竭住院 6 个月后的生活质量评估：来自 REPORT-HF（国际心力衰竭治疗纵向观察评估医疗实践注册研究）的分析。
Eur J Heart Fail. 2022 Jun;24(6):1020-1029. doi: 10.1002/ejhf.2508. Epub 2022 May 12.
2
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.恩格列净对急性心力衰竭住院患者症状、身体限制和生活质量的影响：来自 EMPULSE 试验的结果。
Circulation. 2022 Jul 26;146(4):279-288. doi: 10.1161/CIRCULATIONAHA.122.059725. Epub 2022 Apr 4.
3
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
4
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂卡格列净治疗心力衰竭：CHIEF-HF 远程、以患者为中心的随机试验。
Nat Med. 2022 Apr;28(4):809-813. doi: 10.1038/s41591-022-01703-8. Epub 2022 Feb 28.
5
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.恩格列净、健康状况和射血分数保留的心力衰竭患者的生活质量：EMPEROR-Preserved 试验。
Circulation. 2022 Jan 18;145(3):184-193. doi: 10.1161/CIRCULATIONAHA.121.057812. Epub 2021 Nov 15.
6
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.钠-葡萄糖协同转运蛋白 2 抑制剂达格列净治疗射血分数保留的心力衰竭：一项多中心随机试验。
Nat Med. 2021 Nov;27(11):1954-1960. doi: 10.1038/s41591-021-01536-x. Epub 2021 Oct 28.
7
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.静脉注射羧麦芽糖铁对缺铁性急性心力衰竭患者健康相关生活质量的影响：AFFIRM-AHF研究结果
Eur Heart J. 2021 Aug 17;42(31):3011-3020. doi: 10.1093/eurheartj/ehab234.
8
Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure.心力衰竭住院患者的临床病程和患者报告结局的性别差异。
JACC Heart Fail. 2021 May;9(5):336-345. doi: 10.1016/j.jchf.2020.12.011. Epub 2021 Mar 10.
9
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.恩格列净与射血分数降低的心力衰竭患者健康相关生活质量结局：EMPEROR-Reduced试验
Eur Heart J. 2021 Mar 31;42(13):1203-1212. doi: 10.1093/eurheartj/ehaa1007.
10
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care: JACC State-of-the-Art Review.解读堪萨斯城心肌病问卷在临床试验和临床护理中的应用：美国心脏病学会最新综述
J Am Coll Cardiol. 2020 Nov 17;76(20):2379-2390. doi: 10.1016/j.jacc.2020.09.542.

评估失代偿性心力衰竭出院后的健康状况：以患者为中心的重点。

Assessing health status after discharge for decompensated heart failure: a patient-centred priority.

机构信息

Division of Cardiovascular Medicine, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Baylor Scott and White Research Institute, Dallas, TX, USA.

出版信息

Eur J Heart Fail. 2022 Jun;24(6):1030-1032. doi: 10.1002/ejhf.2521. Epub 2022 May 13.

DOI:10.1002/ejhf.2521
PMID:35481937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9299400/
Abstract

This article refers to ‘Quality of life assessed 6 months after hospitalisation for acute heart failure: an analysis from REPORT-HF (international REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure)’ by C.D. McNaughton , published in this issue on pages 1020–1029.

摘要

本文参考了 C.D. McNaughton 发表于本期第 1020-1029 页的文章“急性心力衰竭住院 6 个月后生活质量评估：来自 REPORT-HF（心力衰竭治疗的纵向观察国际登记以评估医疗实践）的分析”。